Opinion|Videos|October 8, 2024
Overview of DAPA ECHO Trial
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients.
- A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 for the DAPA ECHO trial in which the effects of dapagliflozin on myocardial performance were studied in patients with nondiabetic heart failure.
- What was the objective of this analysis?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. What are the key clinical implications in using dapagliflozin in patients with nondiabetic heart failure?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
2
CVS Pharmacy Completes Acquisition of Select Rite Aid Locations
3
ESMO Congress Marks 50 Years by Showcasing the Future of Cancer Care: Vivek Subbiah, MD
4
Medical School Diversity Declines Following Affirmative Action Repeal
5
